Finding disease-modifying drugs for Parkinson's disease
This article was originally published in Start Up
Parkure Ltd., based in a small lab in Edinburgh, Scotland, will use its fruit fly assay to find new Parkinson’s disease treatments from old drugs, with an aim to slow or even reverse the course of this devastating CNS disorder.
You may also be interested in...
Parkinson’s disease remains a significant undermet, attractive opportunity for drug developers, including early-stage biotechs. Profiles of MentiNova, Parkure and Prexton Therapeutics.
Emerging Company Profile: Gadeta, a Dutch spin-out from University Medical Centre Utrecht, launched earlier this year to develop modified T-cell-based therapies that target metabolic dysregulation in solid and hematological malignancies.
PeptiMimesis is developing first-in-class transmembrane therapeutic peptides with potential in immuno-oncology, oncology and immune diseases. Its technology is based on research showing that targeting the transmembrane domain using a single peptide can block several of the processes involved in the development of cancer by disrupting dimerization of target receptors, impairing the formation of receptor complexes and indirectly blocking the subsequent signaling pathways